Santhera Pharmaceuticals has received approval from the Italian Medicines Agency (AIFA) for the reimbursement of AGAMREE® (Vamorolon) in the treatment of Duchenne Muscular Dystrophy (DMD) for patients aged four and older. This innovative molecule aims to deliver the anti-inflammatory benefits typically associated with glucocorticoids while minimizing the risk of adverse effects common to this class of therapies. DMD is a severe genetic disorder characterized by progressive muscle degeneration and reduced life expectancy due to respiratory and cardiac complications.

The significance of this approval is underscored by the results from the VISION-DMD Phase 2b study, where AGAMREE demonstrated a statistically significant improvement in the Time to Stand (TTSTAND) metric compared to placebo (p = 0.002) after 24 weeks. Long-term data presented at the Muscular Dystrophy Association (MDA) conference in March 2026 indicated that AGAMREE maintained efficacy comparable to standard corticosteroids while exhibiting a differentiated safety profile. Notably, patients treated with AGAMREE showed a significantly lower incidence of vertebral fractures (8.1% vs. 41.9% for Deflazacort, p = 0.0082) and maintained normal growth patterns, suggesting an advantageous risk-benefit ratio.

The approval of AGAMREE not only enhances treatment options for DMD but also represents a pivotal shift in the therapeutic landscape for rare neuromuscular diseases. As Santhera expands access across major European markets, this development may accelerate research into dissociative corticosteroids and their potential applications in other inflammatory conditions, potentially influencing drug development timelines and strategies in the field of aging and muscle degeneration therapies.

Source: globenewswire.com